Bristol Myers Squibb Discloses Patient Death in Early CAR-T Trial

A single patient death in an early-stage CAR-T study is a reminder that the sector's clinical risk is not confined to small biotechs; even a large-cap developer absorbs a visible share-price hit on disclosure. The reaction is notable precisely because no trial details were given, leaving the market to price uncertainty rather than known facts. Whether Bristol Myers Squibb follows with fuller disclosure — and whether the program's timeline shifts — is the open question for anyone tracking CAR-T pipelines.